Hepatocellular Carcinoma Treated With Iodine-125 Implantation

Status Completed

Clinical Trial Summary

To prospectively evaluate whether use of combined radiofrequency ablation (RFA) and percutaneous iodine-125 (125I) seeds implantation results in better survival compared with use of RFA alone in patients with hepatocellular carcinoma.

Clinical Trial Description

This study was local ethical committee approved; all patients gave written informed consent. A total of 136 patients were randomly assigned to undergo RFA-125I (n = 68; 42 men, 26 women; mean age, 50.7 years; age range, 29-73 years) or RFA alone (n = 68; 47 men, 21 women; mean age, 48.9 years; age range, 30-74 years). Patients with viable tumors at computed tomography (CT) 4 weeks after treatment received additional treatment. Rates of local tumor progression and overall survival were evaluated by using Kaplan-Meier and log-rank tests, respectively. The relative prognostic significance of variables in predicting overall survival and the time to tumor recurrence or metastasis were assessed with multivariate Cox proportional hazards regression and logistic regression analyses, respectively. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01717729
Study type	Interventional
Source	The Second People's Hospital of GuangDong Province
Contact
Status	Completed
Phase	Phase 3
Start date	January 2000
Completion date	October 2012

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01020812` - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma	Phase 1/Phase 2
Recruiting	`NCT04443322` - Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )	N/A
Completed	`NCT02305459` - CIRSE Registry for SIR-Spheres Therapy
Terminated	`NCT00791544` - Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT04682847` - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Completed	`NCT02424955` - Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation	N/A
Completed	`NCT03775863` - AFP Model and Liver Transplantation.
Not yet recruiting	`NCT04825470` - Liver Transplantation for Unresectable GIST Liver Metastases	N/A
Recruiting	`NCT06144385` - A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma	Phase 1
Completed	`NCT03178409` - Combined HCC-MFCCC	N/A
Suspended	`NCT04955808` - Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Recruiting	`NCT01380392` - The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma	N/A
Withdrawn	`NCT01744639` - Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation	N/A
Completed	`NCT01482442` - SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma	Phase 3
Active, not recruiting	`NCT01272557` - Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial	Phase 2
Completed	`NCT00328770` - De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma	Phase 2/Phase 3
Completed	`NCT05681234` - Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma	N/A
Terminated	`NCT00767234` - Permission to Collect Blood Over Time for Research	N/A
Active, not recruiting	`NCT02465060` - Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Phase 2
Recruiting	`NCT04288323` - Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis	Phase 4